Merck, Inc.
🇵🇭Philippines
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00783393
MK0524 Asthma POC Study (0524-008)(COMPLETED)
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00783601
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00781846
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
Completed
- Conditions
- Psychosis
- Interventions
- Drug: SCH 900460
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00780585
A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)
Phase 2
Completed
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT00779129
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
Phase 4
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: Remicade
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00778869
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)
Phase 1
Completed
- Conditions
- Hodgkin DiseaseLymphoma, Non-HodgkinNeoplasms
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00779584
Assessment of Long-Term Infliximab for Psoriasis (P05319)
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 660
- Registration Number
- NCT00779675
Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1
- Registration Number
- NCT00779285
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
Phase 4
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: Remicade
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00779935
© Copyright 2025. All Rights Reserved by MedPath